Blenrep (belantamab mafodotin) combinations receive positive CHMP opinion in relapsed/refractory multiple myeloma

Published: 23 May 2025 by GSK press release

Abstract:

Positive opinion supported by superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7.

Copyright © Therapists Africa 2025